Amyotrophic Lateral Sclerosis Market to Register Rapid Growth | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals, companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

{Delhi, India} To strategically aid Amyotrophic Lateral Sclerosis companies developing drugs for Amyotrophic Lateral Sclerosis, DelveInsight launched a report titled as “Amyotrophic Lateral Sclerosis Market Insight, Epidemiology And Market Forecast - 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Amyotrophic Lateral Sclerosis market.

Get a Free sample for the Amyotrophic Lateral Sclerosis Market Report

Key Highlights from Amyotrophic Lateral Sclerosis market Report:

• During the forecast period (2019–2032), the overall Amyotrophic Lateral Sclerosis size within the United States is projected to expand at a compound annual growth rate (CAGR) of 21.0%.
• Within the forecast period, there is an expected increase in the Amyotrophic Lateral Sclerosis market size in the United States, rising from USD 369 million recorded in 2021.
• Key Amyotrophic Lateral Sclerosis Companies: Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, and others
• Key Amyotrophic Lateral Sclerosis Therapies: Engensis (VM202), SAR443820/DNL788, TPN-101, Latozinemab (AL001/GSK4527223), PrimeC, Tofersen (BIIB067), ION363, NurOwn (MSC-NTF cells), Reldesemtiv, Pegcetacoplan (APL-2), Gold Nanocrystals/CNM-Au8, AP-101, MN-166 (ibudilast), and others

Amyotrophic Lateral Sclerosis Country based Treatment Overview: 

The Amyotrophic Lateral Sclerosis market research report provides current treatment practices, emerging drugs, Amyotrophic Lateral Sclerosis market share of the individual therapies, current and forecasted Amyotrophic Lateral Sclerosis market Size from 2019 to 2032 segmented by seven major markets.

Lou Gehrig's disease, often known as amyotrophic lateral sclerosis (ALS), is a collection of uncommon neurological disorders primarily affecting the nerve cells (neurons) in charge of voluntary muscular movement. Movements like chewing, walking, and talking are produced by voluntary muscles. Since the illness is progressive, the symptoms worsen with time.

 To Know in detail about the Amyotrophic Lateral Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Amyotrophic Lateral Sclerosis Market Forecast

Amyotrophic Lateral Sclerosis Epidemiology Insights: 

The Amyotrophic Lateral Sclerosis epidemiology section offers insights into the past and present patient population affected by the disease, along with predicted trends across seven major countries. It assists in understanding the reasons behind current and anticipated trends by analyzing multiple studies and opinions from key experts.

• In 2021, the total diagnosed prevalent cases of Amyotrophic Lateral Sclerosis in the 7MM and China were 59,130 and 29,095 respectively. These numbers are projected to grow at a CAGR of 1.3% and 0.6% during the study period from 2019 to 2032.
• In 2021, among the EU-4 and the United Kingdom nations, Germany recorded the highest diagnosed prevalent instances of Amyotrophic Lateral Sclerosis with 5,398 cases, trailed by the UK (4,561) and Italy (4,478). Conversely, Spain exhibited the lowest number of cases with 3,270 in 2021 which is expected to grow by 2032.
• The Amyotrophic Lateral Sclerosis epidemiology based on gender analyzed that males are more affected than females in case of Amyotrophic Lateral Sclerosis 

Amyotrophic Lateral Sclerosis Epidemiology Segmentation:

• Total Prevalence of Amyotrophic Lateral Sclerosis
• Prevalent Cases of Amyotrophic Lateral Sclerosis by severity
• Gender-specific Prevalence of Amyotrophic Lateral Sclerosis
• Diagnosed Cases of Episodic and Chronic Amyotrophic Lateral Sclerosis 

Download the report to understand which factors are driving Amyotrophic Lateral Sclerosis epidemiology trends @ Amyotrophic Lateral Sclerosis Epidemiology Forecast

Amyotrophic Lateral Sclerosis Drugs and Key Companies

• Engensis (VM202): Helixmith
• SAR443820/DNL788: Sanofi/Denali Therapeutics
• TPN-101: Transposon Therapeutics
• Latozinemab (AL001/GSK4527223): Alector/GSK
• PrimeC: NeuroSense Therapeutics
• Tofersen (BIIB067): Biogen/Ionis
• ION363: Ionis Pharmaceuticals
• NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics
• Reldesemtiv: Cytokinetics/Astellas Pharma
• Pegcetacoplan (APL-2): Apellis Pharmaceuticals
• Gold Nanocrystals/CNM-Au8: Clene Nanomedicine Biosciences
• AP-101: AL-S Pharma
• MN-166 (ibudilast): MediciNova

Emerging Amyotrophic Lateral Sclerosis drugs Uptake:

• The Drug Uptake section of the Amyotrophic Lateral Sclerosis report provides an in-depth analysis of both the available Amyotrophic Lateral Sclerosis drugs in the market and those in the late stages of development (Phase-III, Phase-II, and Phase I/II).
• In September 2022, The FDA in the United States granted approval for RELYVRIO to treat ALS. RELYVRIO, a combination of sodium phenylbutyrate and taurursodiol, demonstrated a reduced rate of decline in daily functioning assessment and showed an association with extended overall survival.
• In May 2022, The US FDA authorized the use of RADICAVA ORS (edaravone) in an oral formulation for the treatment of ALS.
• Amyotrophic Lateral Sclerosis treatments anticipated for potential launch within the projected period encompass Tofersen, ION363, NurOwn, Masitinib, among other potential therapies. 

Discover more about therapies set to grab major Amyotrophic Lateral Sclerosis market share @ Amyotrophic Lateral Sclerosis Treatment Market

Amyotrophic Lateral Sclerosis Market Forecast:

• Potential Amyotrophic Lateral Sclerosis treatments are being developed in the mid- and late stages and could soon be released. The main participants in the market are Verdiperstat (Biohaven Pharmaceuticals), Masitinib (AB Science), Gold Nanocrystals/CNM-Au8 (Brainstorm-Cell Therapeutics), Tofersen/BIIB067 (Biogen/Ionis Pharmaceuticals), and others. This could lead to a rise in the market size in the upcoming years, helped along by a rise in the number of people with Amyotrophic Lateral Sclerosis diagnosis.
• RADICAVA (edaravone) has been an effective therapy for ALS. Recently, oral RADICAVA got approved in the US for the treatment of patients with ALS to increase the patient compliance.
• Most of the 7MM possess their own ALS registries, thereby providing a near precise country-wise number for diagnosed prevalent cases of the disease

Scope of the Amyotrophic Lateral Sclerosis Market Report: 

• Geography Coverage: 7MM
• Study Period: 2019-2032
• Amyotrophic Lateral Sclerosis CAGR: 21% in United States
• Key Amyotrophic Lateral Sclerosis Companies: Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, AI Therapeutics, and others.

To know more about Amyotrophic Lateral Sclerosis companies working in the treatment market, visit @ Amyotrophic Lateral Sclerosis Clinical Trials and Therapeutic Assessment

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Amyotrophic Lateral Sclerosis market landscape.

• Gain Competitive Edge in Indication Market: Understand the current landscape of the Amyotrophic Lateral Sclerosis market, including the competitive environment, key companies developing drugs for Amyotrophic Lateral Sclerosis, and their strategies. By analyzing market dynamics, treatment approaches, and emerging Amyotrophic Lateral Sclerosis therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities: Analyzing epidemiological trends, country wise patient journeys and existing treatment practices can help in identifying gaps and opportunities within the Amyotrophic Lateral Sclerosis market. This involves recognizing areas where current Amyotrophic Lateral Sclerosis treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Amyotrophic Lateral Sclerosis. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making: Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success: Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Amyotrophic Lateral Sclerosis market with clarity and purpose.

Related Reports:

Amyotrophic Lateral Sclerosis Pipeline  

"Amyotrophic Lateral Sclerosis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Amyotrophic Lateral Sclerosis market. A detailed picture of the Amyotrophic Lateral Sclerosis pipeline landscape is provided, which includes the disease overview and Amyotrophic Lateral Sclerosis treatment guidelines. 

Amyotrophic Lateral Sclerosis Epidemiology 

DelveInsight's 'Amyotrophic Lateral Sclerosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Amyotrophic Lateral Sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Gaurav Bora

Email: info@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/consulting